C摩尔为今年以来募资金额最多的科创板公司，首发募集资金达80.00亿元，募资主要投向摩尔线程新一 代自主可控AI训推一体芯片研发项目，摩尔线程新一代自主可控图形芯片研发项目，摩尔线程新一代 自主可控AISoC芯片研发项目等；其次是西安奕材，募资金额为46.36亿元，募资主要用于西安奕斯伟 硅产业基地二期项目，使用部分募集资金进行现金管理等。募资金额较多的还有沐曦股份、禾元生物、 屹唐股份等，分别募资41.97亿元、25.99亿元、24.97亿元。 | 代码 | 简称 | 发行日期 | 发行价（元） | 发行市盈率（倍） | 募集资金（亿元） | | --- | --- | --- | --- | --- | --- | | 688795 | C摩尔 | 2025.11.24 | 114.28 | | 80.00 | | 688783 | 西安奕材 | 2025.10.16 | 8.62 | | 46.36 | | 688802 | 沐曦股份 | 2025.12.05 | 104.66 | | 41.97 | | 688765 | 禾元生物 | 2025.10.14 | 29.06 | | 25.99 | | ...

格隆汇12月3日｜有投资者在互动平台向禾元生物提问：公司和国药控股的合作中，国药控股是作为合 同指定区域的独家代理，负责指定区域的药品销售，还是只是负责指定区域的药品配送，药品的销售推 广是由公司自己负责推销？这和贝达药业的合作模式是一样的吗？ 禾元生物回复称，公司已与国药控股、贝达药业等多家药品经销商签订经销协议，完成了全国30余个省 市区域的销售网络布局。国药控股是公司在特定区域的商业化合作伙伴。双方正在积极开展产品的学术 推广、市场拓展及渠道建设等相关工作，共同推动产品的市场覆盖和临床应用。 ...

Group 1 - The core viewpoint of the article highlights the collaboration between He Yuan Bio and China National Pharmaceutical Group (Sinopharm) as a commercial partner in specific regions, focusing on product promotion and market expansion [1] - He Yuan Bio has established a sales network across more than 30 provinces and cities in China through agreements with multiple distributors, including Sinopharm and Betta Pharmaceuticals [1] - The company is actively engaged in academic promotion, market development, and channel construction with Sinopharm to enhance product market coverage and clinical application [1]

Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

Core Viewpoint - The biopharmaceutical sector experienced a slight increase of 0.23% on December 1, with He Yuan Bio leading the gains. The Shanghai Composite Index rose by 0.65%, while the Shenzhen Component Index increased by 1.25% [1]. Group 1: Market Performance - The biopharmaceutical sector's performance on December 1 showed a mixed trend, with notable gainers including He Yuan Bio, which closed at 81.60 with a rise of 3.29%, and Kanghua Bio, which closed at 84.21 with a rise of 2.93% [1]. - The overall trading volume in the biopharmaceutical sector was significant, with He Yuan Bio achieving a transaction amount of 336 million yuan and Kanghua Bio reaching 351 million yuan [1]. Group 2: Individual Stock Performance - The table of individual stock performance indicates that several companies in the biopharmaceutical sector saw positive price movements, with Te Bao Bio and Wu Xi Jing Hai also recording increases of 2.81% and 2.51%, respectively [1]. - Conversely, some companies faced declines, such as Rong Chang Bio, which fell by 4.47%, and Bai Pu Sai Si, which decreased by 3.65% [2]. Group 3: Capital Flow - The biopharmaceutical sector experienced a net outflow of 273 million yuan from institutional investors, while retail investors contributed a net inflow of 178 million yuan [2]. - The capital flow data highlights that He Yuan Bio attracted a net inflow of 51.47 million yuan from institutional investors, despite a net outflow from retail investors [3].

Core Insights - The total amount raised by companies on the STAR Market this year has reached 27.013 billion yuan, with an average fundraising of 2.078 billion yuan per company [1][2] - The company with the highest fundraising amount is Moer Technology, which raised 8 billion yuan primarily for AI chip development projects [1] - The average initial offering price of STAR Market stocks this year is 27.96 yuan, with the highest being 114.28 yuan for Moer Technology [1][2] Fundraising Overview - A total of 13 companies have issued new shares on the STAR Market this year, with 9 companies raising over 1 billion yuan and 3 companies raising between 500 million yuan and 1 billion yuan [1] - The companies with significant fundraising amounts include Moer Technology (8 billion yuan), Xi'an Yicai (4.636 billion yuan), and Heyuan Bio (2.599 billion yuan) [1] Pricing and Valuation - The average issuance price-to-earnings (P/E) ratio for the issued STAR Market companies is 88.97 times, with a median of 40.46 times [2] - The highest P/E ratio recorded is 519.12 times for Bai'ao Saitou, with 4 companies exceeding the industry average P/E ratio [2] Geographic Distribution - The majority of the issued STAR Market companies are concentrated in Beijing, Hubei, and Guangdong, with 4, 2, and 2 companies respectively [2] - The top fundraising regions are Beijing (12.625 billion yuan), Shaanxi (4.636 billion yuan), and Hubei (3.767 billion yuan) [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio has experienced fluctuations in stock price and trading volume, with a recent increase of 2.02% in its share price, reaching 80.64 CNY per share, while the total market capitalization stands at 28.829 billion CNY [1] - As of October 28, 2025, He Yuan Bio's main business involves the research, production, and sales of plant-derived human serum albumin using rice endosperm cell recombinant protein expression technology, with 75.44% of its revenue coming from recombinant human albumin [1][2] - The company has seen a significant increase in the number of shareholders, with a total of 47,100 shareholders as of October 28, representing an increase of 84,075% compared to the previous period [2] Group 2 - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.6608 million CNY, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million CNY, also a decrease of 8.44% year-on-year [2] - The stock has seen a decline of 11.48% year-to-date, with a recent 5-day increase of 2.71% and a 20-day decline of 31.60% [1] - The company operates within the pharmaceutical and biological industry, specifically in the blood products sector, and is categorized under several concepts including near-term new shares and innovative drugs [2]

Market Overview - The biopharmaceutical sector increased by 0.36% compared to the previous trading day, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Performance - Jindike (688670) saw a closing price of 30.90, with a significant increase of 20.00% and a trading volume of 192,400 shares, amounting to a transaction value of 572 million [1] - Rongchang Bio (688331) closed at 92.25, up 5.43%, with a trading volume of 68,800 shares and a transaction value of 635 million [1] - Sanofi (688336) closed at 68.39, up 4.59%, with a trading volume of 74,400 shares and a transaction value of 510 million [1] - Other notable performers include Olin Bio (616889) with a 4.43% increase and Hualan Bio (301207) with a 3.21% increase [1] Fund Flow Analysis - The biopharmaceutical sector experienced a net inflow of 20.94 million from institutional investors, while retail investors saw a net outflow of 57.02 million [2] - Jindike had a net inflow of 57.00 million from institutional investors, despite a net outflow of 19.76 million from retail investors [3] - Rongchang Bio also saw a net inflow of 32.94 million from institutional investors, with retail investors withdrawing 25.48 million [3]

Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a decline in financing net purchases and a decrease in revenue and net profit for the first nine months of 2025 [1][2] Group 2 - On November 25, He Yuan Bio's stock rose by 0.99%, with a trading volume of 361 million yuan [1] - The financing data on November 25 showed a financing purchase amount of 34.16 million yuan and a financing repayment of 64.34 million yuan, resulting in a net financing purchase of -30.18 million yuan [1] - As of November 25, the total balance of margin trading for He Yuan Bio was 313 million yuan, accounting for 9.87% of its circulating market value [1] Group 3 - As of October 28, the number of shareholders for He Yuan Bio was 47,100, an increase of 84,075% compared to the previous period [2] - The average circulating shares per person decreased to 869 shares, a reduction of 99.85% from the previous period [2] - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.66 million yuan, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million yuan, a year-on-year decrease of 8.44% [2]

Core Insights - The total amount raised by companies on the STAR Market this year has reached 25.746 billion yuan, with an average fundraising of 2.146 billion yuan per company [1][2] - The company with the highest fundraising amount is Moer Technology, which raised 8 billion yuan primarily for AI chip development projects [1] - The average initial offering price of STAR Market stocks this year is 28.07 yuan, with the highest price being 114.28 yuan for Moer Technology [1][2] Fundraising Overview - A total of 12 companies have issued new shares on the STAR Market this year, with 8 companies raising over 1 billion yuan and 3 companies raising between 500 million yuan and 1 billion yuan [1] - The companies with significant fundraising amounts include Moer Technology (8 billion yuan), Xi'an Yicai (4.636 billion yuan), and Heyuan Biology (2.599 billion yuan) [1] Pricing and Valuation - The average issuance price for STAR Market stocks is 28.07 yuan, with one company priced above 50 yuan and another above 100 yuan [1] - The highest issuance price is 114.28 yuan for Moer Technology, while the lowest is 8.45 yuan for Yitang Co. [1][2] Earnings Ratios - The issuance price-earnings ratio for STAR Market companies ranges from 6.14 to 71.42, with an average of 35.20 and a median of 33.41 [2] - C Hengkun has the highest issuance P/E ratio at 71.42, while five companies have P/E ratios below the industry average [2] Geographic Distribution - The majority of companies that have issued shares are located in Beijing, Hubei, and Guangdong, with 3, 2, and 2 companies respectively [2] - The top fundraising regions are Beijing (11.358 billion yuan), Shaanxi (4.636 billion yuan), and Hubei (3.767 billion yuan) [2]